Can we help you find something?

Can we help you find something?

Search Results

37 results match your criteria

  1. Capital Health Surgical Group

    Two Capital Way, Suite 356
    Pennington, NJ 08534
    United States

    609-537-6000

  2. Capital Health Surgical Group - Breast Surgery

    Two Capital Way, Suite 505
    Pennington, NJ 08534
    United States

    609-537-6700

  3. Capital Health – Behavioral Health Specialists

    1445 Whitehorse-Mercerville Road, Suite 111
    Hamilton, NJ 08619-3835
    United States

    609-689-5725

  4. Capital Health – Rheumatology Specialists

    Two Capital Way, Suite 550
    Pennington, NJ 08534
    United States

    609-303-4360

  5. Capital Institute for Neurosciences

    Two Capital Way
    Suite 456
    Pennington, NJ 08534
    United States

    609-394-6000

  6. Center for Comprehensive Breast Care

    One Capital Way
    Pennington, NJ 08534
    United States

    609-537-6767
  7. Oasis Salon & Wellness Spa

    Oasis Salon & Wellness Spa

    One Capital Way
    Pennington, NJ 08534
    United States

    609-537-6544

Capital Health Earns National Reaccreditation from the Commission on Cancer of the American College of Surgeons

Capital Health Cancer Center, located at Capital Health Medical Center – Hopewell, has again received national accreditation from the Commission on Cancer (CoC), a quality program of the American College of Surgeons (ACS) for another three-year term.

Gynecologic Cancer Specialist Joins Capital Health Cancer Center

Dr. Joyce Varughese, a board certified, fellowship trained gynecologic oncologist, has joined Capital Health Surgical Group and is now part of the nationally accredited Capital Health Cancer Center, located at Capital Health Medical Center – Hopewell.

KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment

KIYATEC, Inc. has announced that Capital Health has joined its U.S. clinical trial, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in glioblastoma (GBM) and anaplastic astrocytoma (AA) patients.

View All News